Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts

Targeted Drug Delivery Partnering 2010-2016 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world's leading healthcare companies.

Trends in targeted drug delivery partnering deals
Top targeted drug delivery deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Targeted Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Targeted Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Targeted Drug Delivery partnering deals.

The report presents financial deal term values for Targeted Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

Full Report Details at
- http://www.fastmr.com/prod/1151734_global_targeted_drug_delivery.aspx?afid=301

The middle section of the report explores the leading dealmakers in the Targeted Drug Delivery partnering field; both the leading deal values and most active Targeted Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 160 online deal records of actual Targeted Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Targeted Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Targeted Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Targeted Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Global Transdermal Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
- Global Injectable Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
- Global Topical Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
- Global Drug Delivery Partnering 2010-2016: Deal trends, players and financials
- Global Regenerative Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts